Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Organon
Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.
- Other Names / Subsidiaries
- Alydia Health
- Forendo Pharma Oy
- Organon NV
- Organon & Co.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.